Strategic partnerships Leverage OBI Pharma USA as a gateway to US and European clinical trial collaborations for novel ADC therapies, highlighting its parent company’s GlycOBI platform and dual-drug ADC capabilities to attract CROs, pharma partners, and biotech sponsors seeking advanced ADC development.

Clinical trial focus Target biopharma companies pursuing unmet medical needs in oncology and ADCs with a narrative around OBI USA’s mission to lead US and European trials, offering specialized trial management, regulatory experience, and access to OBI’s GlycOBI technology for homogeneous ADC design.

Technology differentiator Highlight GlycOBI and DUOR platform advantages as a unique selling point for partnerships, emphasizing rapid plug-and-play conjugation and multi-mechanism payload connections to create competitive, next‑gen ADC solutions.

Recovery with small team Position OBI USA as a focused, efficient operations hub with a lean team capable of rapid alignment with sponsor timelines, complemented by the parent company’s broader expertise to reassure potential clients of capability and scale when needed.

Market visibility Capitalize on recent conference momentum from AACR 2026 and World ADC Summit communications to initiate follow-up outreach with attendees, consortiums, and potential license or collaboration discussions leveraging the company’s ongoing research and preclinical data.